Search | Clinical Trials Finder

Conditions: Schizophrenia
Interventions: MEM 3454, Placebo for MEM 3454; Drug
Lead sponsor: Memory Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Uveitis
Interventions: AIN457, Placebo AIN457; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Appendicitis, Children
Interventions: Patient Activation Tool; Other
Lead sponsor: Peter Minneci; Other
Eligibility: 7 Years to 17 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Covid19
Interventions: BNT162b2 vaccine, JNJ-78436735 Vaccine; Biological
Lead sponsor: Giselle Guerra; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Conditions Influencing Health Status
Interventions: Teach-back; Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 254 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Endocrine Tumors
Interventions: lanreotide (Autogel formulation), Placebo; Drug
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 8
States / cities: Los Angeles, California • Iowa City, Iowa • Baltimore, Maryland + 5 more

Conditions: Hypercholesterolemia
Interventions: Alirocumab, Placebo (for alirocumab), Lipid Modifying Therapy (LMT); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 486 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 26
States / cities: Bell Gardens, California • Long Beach, California • Los Angeles, California + 21 more

Conditions: Age-Related Macular Degeneration
Interventions: Sub-retinal transplantation of MA09-hRPE cells, tacrolimus and mycophenolate mofetil, Placebo tacrolimus and mycophenolate mofetil, Sham Surgery; Biological · Drug · Procedure
Lead sponsor: Astellas Institute for Regenerative Medicine; Industry
Eligibility: 50 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Acne, Patient Compliance
Interventions: Text message reminders; Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 12 Years to 30 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 2
States / cities: Dallas, Texas

Conditions: Alzheimer Disease
Interventions: Placebo oral tablet, Simufilam 100 mg tablet, Simufilam 50 mg oral tablet; Drug
Lead sponsor: Cassava Sciences, Inc.; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 9
States / cities: Gilbert, Arizona • Surprise, Arizona • Miami, Florida + 6 more

Conditions: Painful Diabetic Neuropathy, Diabetes Mellitus
Interventions: Active: WST-057 4mL (146 mg pirenzepine free base monohydrate) topical solution, Placebo: WST-057 4mL topical solution; Drug
Lead sponsor: WinSanTor, Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Surgical Site Infection, Pancreatic Neoplasms, Pancreatic Cancer, Chemotherapy Effects, Chemoradiation, Surgical Wound, Wound Complication
Interventions: Prevena Peel & Place Dressing, Standard Closure of the Surgical Incision; Device · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Major Depressive Disorder
Interventions: Vortioxetine, Duloxetine, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 611 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 38
States / cities: Beverly Hills, California • Irvine, California • Santa Ana, California + 35 more

Conditions: Neuropathic Pain
Interventions: BMS-741672, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 8
States / cities: Tustin, California • Palm Beach Gardens, Florida • St. Petersburg, Florida + 5 more

Conditions: Nausea, Vomiting
Interventions: Enterra Therapy System; Device
Lead sponsor: Enterra Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 12
States / cities: Scottsdale, Arizona • Los Angeles, California • Newport Beach, California + 9 more

Conditions: Hepatitis C
Interventions: GI-5005; Biological
Lead sponsor: GlobeImmune; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 5
States / cities: Pasadena, California • Denver, Colorado • Miami, Florida + 2 more

Conditions: Type 1 Diabetes Mellitus
Interventions: AVT001, Placebo; Drug · Other
Lead sponsor: Avotres Inc.; Industry
Eligibility: 16 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Stomatitis, Oral Mucositis
Interventions: SNX-1012 (meclocycline sulfosalicylate), placebo; Drug
Lead sponsor: Mucosal Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 9
States / cities: Rancho Mirage, California • Bridgeport, Connecticut • Norwich, Connecticut + 6 more

Conditions: Postbariatric Hypoglycemia
Interventions: exendin 9-39, Placebo; Drug · Other
Lead sponsor: Eiger BioPharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 5
States / cities: Palo Alto, California • Aurora, Colorado • Baltimore, Maryland + 2 more

Conditions: Rhinitis, Allergic, Perennial
Interventions: Ciclesonide, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years and older
Enrollment: 418 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 23
States / cities: Encinitas, California • Long Beach, California • Los Angeles, California + 19 more

Conditions: Allergic Rhinitis Due to Grass Pollens
Interventions: 300 IR, Placebo; Drug
Lead sponsor: Stallergenes Greer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 473 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 19
States / cities: Normal, Illinois • Lexington, Kentucky • Owensboro, Kentucky + 16 more

Conditions: Lymphoma,Non-Hodgkin
Interventions: Copanlisib (Aliqopa, BAY80-6946), Placebo, Rituximab; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 458 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 16
States / cities: West Covina, California • Ashland, Kentucky • Louisville, Kentucky + 10 more

Conditions: Prostate Cancer
Interventions: exisulind, conventional surgery, neoadjuvant therapy; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 40 Years and older · Male only
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Ulcerative Colitis
Interventions: BBT-401-1S first and then Placebo, Placebo first and then BBT-401-1S; Drug
Lead sponsor: Bridge Biotherapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 11
States / cities: Sacramento, California • Ventura, California • Boca Raton, Florida + 8 more

Search by objective public record fields.

A Single-Center, Double-Blind (DB) Study of MEM 3454 on P50 Sensory Gating and Mismatch Negativity in Schizophrenia Patients

38 Week Extension Study to CAIN457C2303

Randomized Controlled Trial of a Patient Activation Tool in Pediatric Appendicitis (Antibiotics Alone vs. Appendectomy)

COVID-19 3rd Dose Vaccine in Transplant Patients

Use of Teach Back to Improve Comprehension of Discharge Instructions for Emergency Patients With Limited Health Literacy

Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy

Study to Evaluate Sub-retinal Transplantation of Retinal Pigmented Epithelial Cells in Patients With Dry AMD

"A Randomized, Controlled, Evaluator-blinded Pilot Study to Evaluate the Effect of Automated Text Message Reminders on Patient Compliance With Topical Medications and Its Efficacy on Skin Disease Control in Adolescents and Adults With Mild to Moderate Acne"

PTI-125 for Mild-to-moderate Alzheimer's Disease Patients

A 12-Week Study of Topical Pirenzepine or Placebo in Type 2 Diabetic Patients (T2DM) With Painful Peripheral Neuropathy

Comparison Between Wound Vacuum Dressing and Standard Closure to Reduce Rates of Surgical Site Infections

Efficacy and Safety of Vortioxetine (Lu AA21004) in the Treatment of Patients With Major Depressive Disorder

BMS-741672 for Diabetic Neuropathic Pain

Chronic Nausea and Vomiting in Patients With Normal Gastric Emptying Using the Enterra® Therapy System (NAVIGATE)

Safety and Efficacy of the Therapeutic Vaccine GI-5005 Versus Placebo for the Treatment of Chronic Hepatitis C Infection

Safety, Tolerability and Potential Efficacy of AVT001 in Patients With Type 1 Diabetes

Efficacy of SNX-1012 in the Treatment of Oral Mucositis

Safety and Efficacy of Exendin 9-39 in Patients With Postbariatric Hypoglycemia

To Assess the Safety and Efficacy of Ciclesonide Applied as a Nasal Spray in the Treatment of Perennial Allergic Rhinitis (BY9010/M1-402)

Study of Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Adult Patients With Allergic Grass Pollen Rhinoconjunctivitis

Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)

Neoadjuvant Exisulind in Treating Patients Who Are Undergoing Radical Prostatectomy for Stage II or Stage III Prostate Cancer

Efficacy and Safety of BBT-401-1S in Ulcerative Colitis